Primer: BillionToOne (BLLN US) - Aug 2026
BillionToOne is a rapidly growing, recently profitable molecular diagnostics company poised to disrupt the prenatal and oncology testing...
91 Views
BillionToOne: More Than 60% Above IPO Pricing, What’s Ahead?
With 2Q earnings coming out this week, we revisit the March surprise: 2025 FY $305M Revenue was 100% YoY. FY2025, there was growth in both...
602 Views
Primer: BillionToOne - 18 May 2026
Genetic testing tool for prenatal screening and cancer therapy selection via blood samples
137 Views
Primer: Benchling - 12 Oct 2026
Software for biotech teams to design, document, and manage scientific experiments and samples
143 Views
BillionToOne (BLLN US): Delayed US & Global Index Inclusion Following Lock‑up
BLLN US has a $4bn market cap and facing initial exclusion from US and Global indices due to low free float and public voting rights, but is...
353 Views